PREVIEW: Small Cap Focus with Charles Duncan

You are Watching:

Small Cap Focus, Full Integration, Personalized Medicine, with Charles Duncan.

In today's market, where good clinical data and milestones are shadowed by financing prospects, Charles Duncan recommends having at least 2 years cash. Charles also presents a few of the most promising small and mid caps he's been keeping his eyes on - including Myriad Genetics (MYGN), Sequanom (SQNM), Illumina (ILMN), Invitrogen (IVGN), Genomic Health (GHDX). Charles and Daniel discuss the opportunity for small and mid caps to become fully integrated specialty pharmaceuticals.

This interview was conducted at the NASDAQ Marketsite, on June 26th, 2008, in New York City.

Featuring: * Charles Duncan, Managing Director and Senior Biotechnology Analyst, JMP Securities * Daniel Teper, Managing Director at Bionest Partners, and Founder & Chairman of BioBusiness.TV

DISCLAIMER:
BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

Category:

Science & Technology

Tags:

• Charles
• Duncan
• MYGN
• SQNM
• ILMN
• IVGN
• GFDX
• Myriad
• Genetics
• Sequanom
• Illumina
• Invitrogen
• Genomic
• Health